Registration number: 06316713

Viscus Medical Limited

Contents

Balance Sheet	1
Notes to the Unaudited Financial Statements	2 to 7

Viscus Medical Limited

(Registration number: 06316713)
Balance Sheet as at 31 July 2026

	Note	2026 £	2025 £
Fixed assets
Tangible assets	4	27	36
Other financial assets	5	25,000	25,000
		25,027	25,036
Current assets
Debtors	6	161,793	163,169
Cash at bank and in hand		18,983	20,693
		180,776	183,862
Creditors: Amounts falling due within one year	7	(16,622)	(19,387)
Net current assets		164,154	164,475
Net assets		189,181	189,511
Capital and reserves
Called up share capital	8	100	100
Retained earnings		189,081	189,411
Shareholders' funds		189,181	189,511

For the financial year ending 31 July 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

•	The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
•	The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 5 October 2026
 

......................................... Dr Scott Glickman Company secretary and director

Viscus Medical Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2026

1	General information

The company is a private company limited by share capital, incorporated in United Kingdom.

The address of its registered office is:
Primrose Cottage
Grendon Road
Aylesbury
Bucks
HP18 0QU

2	Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

Viscus Medical Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2026

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Equipment	25% reducing balance

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Viscus Medical Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2026

3	Staff numbers

The average number of persons employed by the company (including the director) during the year, was 0 (2025 - 0).

Viscus Medical Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2026

4	Tangible assets

	Furniture, fittings and equipment  £	Total £
Cost or valuation
At 1 August 2025	657	657
At 31 July 2026	657	657
Depreciation
At 1 August 2025	621	621
Charge for the year	9	9
At 31 July 2026	630	630
Carrying amount
At 31 July 2026	27	27
At 31 July 2025	36	36

5	Other financial assets (current and non-current)

	Financial assets at cost less impairment £	Total £
Non-current financial assets
Cost or valuation
Additions	25,000	25,000
At 31 July 2026	25,000	25,000
Impairment
Carrying amount
At 31 July 2026	25,000	25,000

Viscus Medical Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2026

6

Debtors

	2026 £	2025 £
Trade debtors	48,793	50,169
Other debtors	113,000	113,000
	161,793	163,169

7

Creditors

Creditors: amounts falling due within one year

	2026 £	2025 £
Due within one year
Taxation and social security	8,129	11,067
Accruals and deferred income	1,760	1,575
Other creditors	6,733	6,745
	16,622	19,387

Viscus Medical Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2026

8	Share capital

Allotted, called up and fully paid shares

	2026		2025
	No.	£	No.	£
Ordinary shares of £1 each	100	100	100	100

9

Dividends

		2026		2025
		£		£
Interim dividend of £Nil (2025 - £Nil) per ordinary share		-		440

10	Related party transactions

Summary of transations with related parties

Common directors
 During the year, the company loaned a related party company with common directors £nil (2025:£15,500). The amount outstanding at the balance sheet date was £113,000 (2025: £113,000)